Friday 6 November 2026 Export RVMD’s income statement to Excel — free account

Revolution Medicines, Inc.

Revolution Medicines, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $11.6 million, down 67.3% from fiscal 2022.

Revenue: +1,188.7%
EPS: −18.0%
Free cash flow: −99.1%
Total debt: +322.7%

Quarter to September 2026, against a year earlier

193.33 15.68 +8.83%

Follow RVMD

Alert me

Market cap: $38.1B
P/E: 0.0×
Fwd P/E: −11.9×
Dividend yield: —
F-score: 4/9
Altman Z: 7.73
Beneish M: −4.29
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Revolution Medicines, Inc. (RVMD) P/S ratio

Alert me on P/S ratio

As of 5 November 2026, Revolution Medicines, Inc. (RVMD) trades at a P/S ratio of 185×. Over the past ten years it has ranged from 1.1× (March 2020) to 1,733× (August 2026); the current reading is higher than 62% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.5×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/RVMD/ps-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Revolution Medicines, Inc. P/S ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/RVMD/metrics/ps-ratio">Revolution Medicines, Inc. (RVMD) P/S ratio — stockrow.com</a></p>

Period	P/S ratio	Change
FY2023	149×	184.12%
FY2022	52.3×	(16.12%)
FY2021	62.4×	23.37%
FY2020	50.5×	3,055.94%
FY2019	1.6×	0.00%
FY2018	1.6×	—

Period	P/S ratio	Change
Sep 2026	211×	41.97%
Dec 2023	149×	53.45%
Jun 2023	96.8×	64.14%
Mar 2023	59.0×	12.81%
16 more quarters	Free account

Against its own ten years

Low 1.1× High 1,733×

Ten-year median 77.7×

Current reading's percentile 62

Company	P/S ratio
INCY Incyte Corporation compare	4.0×
ONC BeOne Medicines Ltd. - Sponsored ADR compare	6.6×
GMAB Genmab A/S Sponsored ADR compare	7.9×
BNTX BioNTech SE Sponsored ADR compare	7.9×
ARGX argenex SE compare	9.5×
RPRX Royalty Pharma PLC compare	11.5×
INSM Insmed, Inc. compare	15.6×
RVMD Revolution Medicines, Inc.	185×
ROIV Roivant Sciences Ltd. compare	3,528×
Biotechnology industry median	9.2×
Healthcare sector median	3.5×
Market median	1.9×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

Revolution Medicines, Inc. (RVMD) P/S ratio

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on RVMD

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on RVMD

Stockrow Weekly